TNFα production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS

Neurology

Volumn 57, Issue 6, 2001, Pages 1129-1131

  Killestein, J ^a   Kalkers, N F ^a   Meilof, J F ^a   Barkhof, F ^a   Van Lier, R A W ^a   Polman, C H ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; BRAIN; CD4+ T LYMPHOCYTE; DISABILITY; FOLLOW UP; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035949353     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.6.1129     Document Type: Article

References (10)

1. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans
2. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity
3. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis
4. Placebo-controlled multicentre randomised trial of interferon-beta-1b in treatment of secondary progressive multiple sclerosis
5. Correlations between monthly enhanced lesion rate and changes in T2 lesion volume in multiple sclerosis
6. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis
7. Increased production of tumor necrosis factor α, and not of interferon γ, preceding disease activity in patients with MS
8. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis
9. + cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
10. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients